Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Adial Pharmaceuticals Inc (ADIL)

Adial Pharmaceuticals Inc (ADIL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,824
  • Shares Outstanding, K 14,393
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,590 K
  • 60-Month Beta 0.70
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.57
Trade ADIL with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.85
  • Growth Rate Est. (year over year) +117,629.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.06 +5.38%
on 03/04/21
3.30 -34.24%
on 02/16/21
-0.18 (-7.68%)
since 02/04/21
3-Month
1.60 +35.60%
on 12/29/20
3.30 -34.24%
on 02/16/21
+0.14 (+6.88%)
since 12/04/20
52-Week
1.00 +116.96%
on 03/18/20
4.00 -45.76%
on 09/29/20
+0.66 (+43.54%)
since 03/04/20

Most Recent Stories

More News
Adial Schedules Town Hall to Discuss Positive Updates Regarding Pharmaceutical Pipeline and Business Expansion

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will host a Town...

ADIL : 2.17 (-7.66%)
ADILW : 0.6600 (unch)
Adial Receives $1.425 Million in Net Proceeds from Exercise of Warrants

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced the exercise...

ADIL : 2.17 (-7.66%)
ADILW : 0.6600 (unch)
Adial Pharmaceuticals Achieves 50% Enrollment in ONWARD(TM) Phase 3 Trial

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it has reached 50% enrollment...

ADIL : 2.17 (-7.66%)
ADILW : 0.6600 (unch)
Adial to File Fast Track Application for AD04 with the FDA

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it...

ADIL : 2.17 (-7.66%)
ADILW : 0.6600 (unch)
Adial Pharmaceuticals Closes Acquisition of Purnovate

Acquisition Expands Adial's Portfolio with Drug Candidates for Treatment of Pain and Addiction

ADIL : 2.17 (-7.66%)
Adial Pharmaceuticals to Present at 23rd Annual ICR Conference

CHARLOTTESVILLE, VA / ACCESSWIRE / January 11, 2021 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development...

ADIL : 2.17 (-7.66%)
ADILW : 0.6600 (unch)
Adial Pharmaceuticals Receives Notice of Allowance for Third U.S. Patent Covering AD04 for the Treatment for Opioid Use Disorder

CHARLOTTESVILLE, VA / ACCESSWIRE / January 11, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions,...

ADIL : 2.17 (-7.66%)
ADILW : 0.6600 (unch)
Adial Pharmaceuticals Reaches 35% Enrollment in ONWARD(TM) Pivotal Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder

ONWARD™ Trial Remains on Track to be Fully Enrolled During Q2 2021

ADIL : 2.17 (-7.66%)
ADILW : 0.6600 (unch)
Adial Pharmaceuticals Appoints Dr. Jack Reich as Head of Regulatory

CHARLOTTESVILLE, VA / ACCESSWIRE / December 15, 2020 / (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced the appointment...

CHIR : 16.56 (-1.90%)
ADIL : 2.17 (-7.66%)
Adial Pharmaceuticals Schedules Business Update Conference Call to Discuss Planned Acquisition of Purnovate and other Recent Developments

CHARLOTTESVILLE, VA / ACCESSWIRE / December 10, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for...

ADIL : 2.17 (-7.66%)
ADILW : 0.6600 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.

See More

Key Turning Points

3rd Resistance Point 2.74
2nd Resistance Point 2.66
1st Resistance Point 2.50
Last Price 2.17
1st Support Level 2.26
2nd Support Level 2.18
3rd Support Level 2.02

See More

52-Week High 4.00
Fibonacci 61.8% 2.85
Fibonacci 50% 2.50
Last Price 2.17
Fibonacci 38.2% 2.15
52-Week Low 1.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar